SELLAS Life Sciences: The AML Platform Is More Interesting Than Binary Event (NASDAQ:SLS)
· seekingalpha.com
SELLAS is advancing a dual-path AML franchise with GPS nearing pivotal Phase 3 REGAL readout and SLS009 progressing. Find out why SLS stock is a buy.
The obvious narrative I see is that SELLAS ( SLS ) is an emerging growth biotech approaching a binary Phase 3 readout for its lead candidate galinpepimut-S (GPS...